In the early days of the coronavirus disease 2019 (COVID-19) pandemic, involvement by neurologists seemed unnecessary. The virus was thought to lead to a respiratory illness, largely sparing the brain and the rest of the nervous system. However, early reports from large outbreaks in China quickly changed this view. A study of more than 200 patients hospitalized in 3 COVID-19–focused hospitals in Wuhan demonstrated that more than one-third experienced a variety of neurologic manifestations, including altered mental status and acute cerebrovascular diseases, most commonly in those with severe respiratory illness.1 These findings quickly changed the perspective of neurologists worldwide and focused efforts toward both understanding the mechanisms responsible for this neurologic involvement and devising systems of care to identify and effectively treat these increasingly recognized complications.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: S. Andrew Josephson, MD, UCSF Department of Neurology, 505 Parnassus Ave, Box 0114, San Francisco, CA 94143 (firstname.lastname@example.org).
Conflict of Interest Disclosures: Dr Josephson reported serving as associate editor for Continuum Audio. Dr Kamel reported serving as co–principal investigator for the National Institutes of Health–funded ARCADIA trial (NINDS U01NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics, serving as a steering committee member for Medtronic’s Stroke AF trial (uncompensated), serving on an end-point adjudication committee for a trial of empagliflozin for Boehringer Ingelheim, and having served on an advisory board for Roivant Sciences related to factor XI inhibition.
You currently have no searches saved.
You currently have no courses saved.